Durvalumab and cediranib with and without olaparib in recurrent ovarian cancer: a phase II proof-of-concept study

Journal:

Nature Communications

Published:

2026-03-16

DOI:

10.1038/s41467-026-70785-6

Affiliations:

7

Authors:

18

Go to article

Institutions	Authors	Share
NIH National Cancer Institute (NCI), United States of America (USA)	12.000000 12.000000	0.67
NIH NCI Center for Cancer Research (CCR), United States of America (USA)	4.000000	0.22
Frederick National Laboratory for Cancer Research (FNLCR), United States of America (USA)	1.000000	0.06
Humanitas San Pio X Hospital, Italy	0.500000	0.03
Icahn School of Medicine at Mount Sinai (ISMMS), MSHS, United States of America (USA)	0.500000	0.03

Interested in Oncology and Carcinogenesis?